Current Edition

CAR T

Gilead’s Kite flies higher as Yescarta leads CAR-T therapy class to earlier lymphoma treatment

Existing CAR-T therapies have been saved for blood cancer patients who’ve tried multiple treatments—until now. With a first-in-class nod, the FDA has cleared Yescarta, a …

Continue Reading →
ASH 2021

ASH: Novartis thinks it knows why Kymriah failed in earlier lymphoma but shifts focus to next-gen CAR-T meds

Kymriah’s shocking failure in earlier lymphoma treatment has raised doubts about the Novartis drug’s potency in light of impressive victories from rival CAR-Ts by Gilead …

Continue Reading →
Bristol Myers

Novartis’ Kymriah flops in earlier lymphoma use, where Gilead, Bristol Myers CAR-T rivals succeeded

Novartis’ Kymriah is losing its shot at a key market expansion opportunity in second-line lymphoma, where CAR-T rivals from Gilead Sciences and Bristol Myers Squibb …

Continue Reading →
Bezos

Clinical Trials for CAR T Cells at Bezos Family Immunotherapy Clinic

David G. Maloney, MD, PhD, medical director of immunotherapy at the Seattle Cancer Care Alliance and member of Fred Hutchinson Research Center, discusses the clinical …

Continue Reading →